GDC-0879 is a novel, potent, and selective B-Raf inhibitor.

SB590885 is a potent B-Raf inhibitor.

TAK-632 is a potent pan-Raf inhibitor.

Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity.

LY03009120 is a potent pan-Raf inhibitor.

SB202190 is a potent p38 MAPK inhibitor.

Ralimetinib is a novel and potent inhibitor of p38 MAPK.

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β.